Firms team up to develop cancer drugs in potential $540M deal

08/6/2013 | Reuters · Genetic Engineering & Biotechnology News

Bayer HealthCare and Compugen signed a preclinical research agreement centered on antibody-based cancer immunotherapies. Bayer will get the rights to further develop and market the drugs arising from the collaboration. The deal entitles Compugen to $10 million upfront and as much as $530 million in milestone fees plus sales royalties.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN